Nigeria Pharmaceuticals and Healthcare Report Q2 2009

Publication Date	April 2009
Publisher	Business Monitor
Product Type	Report
Pages	86
ISBN Number	not applicable
Product Code	BMI03686

Buy this product or for assistance call +44 20 7060 7474

PDF £250.00$410 | €277

FAX Order above formats by FAX

Summary

For this Q209 Pharmaceutical and Healthcare Nigeria report, BMI has forecast that the total drug market will increase from US$633mn in 2008 to US$695mn by 2013, representing a compound annual growth rate (CAGR) of 1.89% in US dollar terms and 3.24% with respect to the Nigerian naira. We believe the main drivers for growth are the various healthcare programmes that have been implemented to increase health awareness and primary care uptake. The promotion of the national health insurance scheme (NHIS) is expected to see renewed drive from the government to boost pharmaceutical spending. Underlining this, we expect healthcare expenditure to rise from US$7.3bn in 2008 to US$8.3bn by 2013.

During December 2008 the teething syrup My Pikin raised alarm when the National Agency for Food, Drug Administration and Control (NAFDAC) confirmed that over 29 infants had died after using it. This has now increased to 80 victims. Barewa Pharmaceuticals, an indigenous drug manufacturer which produced My Pikin, has been shut down, while the owner of Nigerian chemical supplier Tranxell has been arrested and accused of providing the illegal and toxic compound diethylene glycol which was used in producing the syrup. Diethylene glycol is normally found in anti-freeze and brake fluid.

Nigeria's pharmaceutical industry has been damaged by counterfeiting since its independence in 1960.

While poor intellectual property (IP) protection and financial mismanagement deters multinational drug companies from releasing patented drugs, it also questions the integrity of indigenous manufacturers. The lack of transparency and compliance in the Nigerian drug industry will not instil confidence into the system, especially at a time when the country is trying to discourage or ban imported medicines in order to promote self-sufficiency.

In January 2009, the health minister of Nigeria, Babatunde Osotimehin, announced that the government will release more funds into the NHIS to encourage rural communities to participate. While low income, poor healthcare access in remote areas and illiteracy form the basis for non-compliance, BMI believes that the government and the NHIS should co-ordinate efforts in educating the rural population about health insurance.

Content

Executive Summary
SWOT Analysis
Nigeria Pharmaceuticals And Healthcare Industry SWOT
Nigeria Political SWOT
Nigeria Economic SWOT
Nigeria Business Environment SWOT
Pharmaceutical Business Environment Ratings
Limits To Potential Returns
Risks To Realisation Of Returns
Market Summary
Regulatory Regime
Import Regime
Recent Regulatory Developments
Intellectual Property Regime
Counterfeit Drugs
Recent Developments in Regards to Counterfeit Drugs
Pricing And Reimbursement Regime
Industry Developments
Epidemiology
HIV/AIDS
Healthcare Sector
Healthcare Provision
Recent Healthcare Sector Developments
Healthcare Reforms
Health Insurance
Traditional African Medicine
Domestic Pharmaceutical Sector
Foreign Pharmaceutical Sector
National Drug Policy
Research and Development
Medical Devices
Recent Developments In The Medical Devices Market
Industry Forecast Scenario
Overall Market Forecasts
Key Growth Factors - Industry
Key Growth Factors - Macroeconomic
Prescription Drug Market Forecast
OTC Drug Market Forecast
Patented Drug Market Forecast
Generic Drug Market Forecast
Export/Import Market Forecasts
Other Healthcare Data Forecasts
Key Risks To BMI's Forecasts
Competitive Landscape
Company Profiles
Multinationals
Pfizer
Novartis
Sanofi-Aventis
GlaxoSmithKline (GSK)
Indigenous Producers
Nigeria-German Chemicals PLC (NGC)
Emzor
Fidson Healthcare
Archy
Neros Pharmaceuticals
Drugfield Pharmaceuticals Limited
Neimeth
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Country Snapshot: Nigeria Demographic Data
Section 1: Population
Section 2: Education And Healthcare
Section 3: Labour Market And Spending Power
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Weighting
Sources
List of Tables
- Table: Middle East And Africa Pharmaceutical Business Environment Ratings
- Table: Leading Causes Of Death In Africa, 2002
- Table: Nigeria Free Zones: Key Incentives
- Table: Nigeria - Drug Market Expenditure, 2003-2013
- Table: Nigeria - Health Expenditure, 2003-2013
- Table: Nigeria - Economic Activity
- Table: Nigeria's - Prescription Drug Market, 2003-2013 (NGNmn unless otherwise stated)
- Table: Nigeria - OTC Market Data Forecasts, 2003-2013 (NGNmn unless otherwise stated)
- Table: Nigeria - Patented Drug Market Indicators, 2003-2013
- Table: Nigeria - Generic Drug Market Indicators, 2003-2013
- Table: Nigeria - Pharmaceutical Trade Balance, 2003-2013
- Table: Nigeria - Other Health Indicators, 2003-2013
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Pharmaceutical Business Environment Indicators
- Table: Weighting Of Components